Chelation Therapy

Chelating (pronounced key-layting) agents are substances which can chemically bond with, or chelate (from the Greek chele, claw), metals, minerals, or chemical toxins from the body. The chelating agent actually encircles a mineral or metal ion and carries it from the body via the urine and feces. Many organic acids found in the body or in foods can act as chelating agents, including acetic acid, ascorbic acid (vitamin C), citric acid, and lactic acid. Natural chelation processes in the body are responsible for such things as the digestion, assimilation, and transport of food nutrients, the formation of enzymes and hormones, and detoxification of toxic chemicals and metals.

Intravenous chelation therapy involves injecting the chelating agent EDTA into the bloodstream for the purpose of eliminating from the body undesirable substances such as heavy metals, chemical toxins, mineral deposits, and fatty plaques (as in the arteries; the agent binds to the calcium in the plaques). EDTA (ethylene diamine tetraacetic acid) is an effective and widely studied chelating agent. It cannot chelate mercury, however, DMSA and DMPS, the chemicals which work intravenously to chelate mercury, are not approved by the FDA.

EDTA is a synthetic amino acid (amino acids are the building blocks of protein) and is approximately one third as toxic to the body as aspirin. Chelation therapy with EDTA was first introduced into medicine in the United States in 1948 as a treatment for the lead poisoning of workers in a battery factory. Shortly thereafter, the U.S. Navy advocated chelation for sailors who had absorbed lead while painting government ships and facilities. The FDA approved IV EDTA chelation as a treatment for lead poisoning.

Physicians administering the chelation for lead toxicity observed that patients who also had atherosclerosis (fatty-plaque buildup on arterial walls) or arteriosclerosis (hardening of the arteries) experienced reductions in both conditions after chelation. Since 1952, IV EDTA chelation has been used to treat cardiovascular disease.

Over 1,800 scientific journal articles have been published on the use of EDTA in intravenous (IV) chelation. In the past 30 years, hundreds of thousands of patients have received this therapy, as delivered by over 1,000 physicians in approximately 3,300,000 IV infusions. EDTA’s success rate in increasing blood circulation is 82%, provided the patients received sufficient chelation.